Plan B
Plan B Price range: $ 60,00 through $ 132,00
Back to products
Progesterone
Progesterone Price range: $ 32,00 through $ 104,00

Podofilox

Price range: $ 25,00 through $ 112,00

Podofilox is a highly effective topical treatment specifically designed for the removal of external genital and perianal warts. The active ingredient works by penetrating the wart tissue and stopping the growth of infected skin cells, leading to the eventual clearance of the lesion. This medication is formulated for direct application to the affected areas, providing a targeted approach to managing skin growths caused by the human papillomavirus. When used as directed, Podofilox helps visible warts shrink and eventually disappear, restoring the natural appearance of the skin. It is a reliable solution for the local management of external condyloma acuminatum, focusing on the effective destruction of unwanted tissue.

Active substance: Podophyllotoxin
SKU: Podofilox Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Podofilox – What You Need to Know

Podofilox belongs to a class of topical antimitotic agents derived from podophyllotoxin. It is indicated for the topical management of external anogenital warts under medical supervision. As a prescription formulation, podofilox is prescribed for selective application to targeted cutaneous lesions rather than internal mucosal surfaces.

This reference document provides objective pharmacologic data and clinical clinical guidelines regarding the properties, administration protocols, and safety profile of topical podofilox 0.5% solution and gel.

Property Specification
Active ingredient Podofilox (0.5%)
Dosage form Topical solution / Topical gel
Route of administration Topical application
Primary purpose Treatment of external anogenital warts
Prescription status Prescription (Rx) only
Storage Store at 68°F to 77°F (20°C to 25°C)

Main uses

Podofilox 0.5% solution and gel are indicated for the topical treatment of external anogenital warts (Condylomata acuminata). These cutaneous lesions are epidermal growths associated with human papillomavirus (HPV) infection located on the penis, perianal regions, or external female genitalia. Podofilox is specifically restricted to external application and is not indicated for the management of internal mucous membrane lesions, including urethral, rectal, or intravaginal warts. Clinical evaluation by a qualified prescriber is required to confirm diagnosis prior to initiating therapy, ensuring that lesions selected for treatment fall within the appropriate anatomical guidelines.

How the drug works

The mechanism of action of podofilox relies on its antimitotic action within proliferating epithelial cells. Podofilox is a purified non-alkaloid toxin isolated from species of Podophyllum. At the cellular level, the compound binds specifically to tubulin, the protein subunit responsible for microtubule assembly. By inhibiting microtubule formation and disrupting the mitotic spindle apparatus, podofilox arrests cell division in metaphase. This pharmacological block halts cellular replication in the affected viral tissue, leading to cellular death, tissue necrosis, and eventual erosion and sloughing of the external hyperplastic wart tissue over consecutive treatment cycles.

How it’s absorbed and eliminated

Pharmacokinetic evaluations demonstrate that systemic absorption following proper topical application of podofilox 0.5% solution or gel is minimal. In clinical pharmacokinetic studies where 0.05 mL of podofilox solution was applied to external genital tissue, peak serum concentrations were low or undetectable in the majority of subjects. However, systemic bioavailability increases if the drug is applied over large surface areas, in excessive quantities, or onto eroded or damaged skin surfaces. Absorbed podofilox undergoes hepatic metabolism and is subsequently excreted through renal and biliary routes. The biological half-life of absorbed podofilox ranges between 1 and 4.5 hours in human subjects.

Dosing schedule

The administration regimen for podofilox follows a strict cyclical dosing schedule. The standard regimen consists of twice-daily applications (every 12 hours) for 3 consecutive days, followed by a 4-day rest period during which no drug is applied. This 7-day cycle may be repeated up to a maximum of 4 total cycles if visible lesion tissue persists. The medication should be applied strictly to the wart tissue using an applicator tip or cotton swab, avoiding surrounding healthy skin. Total daily dosage should not exceed 0.5 mL of solution or 0.5 g of gel, and the total treated area should not exceed 10 square centimeters per daily application.

First days of treatment

During the initial days of podofilox therapy, localized inflammatory changes typically manifest at the application site. Patients usually notice erythema, mild swelling, and epithelial erosion as the active antimitotic agent induces tissue necrosis within the wart. These local mucosal and cutaneous reactions generally peak during or immediately following the 3-day treatment window. Mild tenderness or a localized burning sensation during application is a standard pharmacologic response rather than an allergic reaction. If superficial erosion occurs, tissue healing typically proceeds during the subsequent 4-day non-treatment interval.

Practical tips

To maximize therapeutic efficacy and minimize localized skin irritation, precise application techniques must be observed. Wash hands thoroughly before and after every application. Allow the targeted skin region to dry completely before applying the formulation. Using the provided applicator or a fine cotton swab, apply sparingly to each lesion, taking care to avoid spreading the product to healthy adjacent cutaneous or mucosal surfaces. Allow the liquid or gel to dry thoroughly before allowing surrounding tissue to come into contact with the area. Never apply occlusive dressings over the treated region unless specifically directed by a healthcare professional.

Adverse reactions

Adverse reactions associated with podofilox are predominantly localized to the application site and stem from its cytotoxic properties. Clinical trial data indicate that the most common adverse events include local pain, burning sensation, erythema, superficial erosion, and localized itching (pruritus). Severe local reactions such as deep ulceration, severe edema, bleeding, or pain during intercourse (dyspareunia) may occur in some individuals. Systemic adverse effects–including nausea, dizziness, or confusion–are exceedingly rare and generally indicate excessive dosage or systemic absorption through compromised skin. Any severe local tissue breakdown warrants immediate medical re-evaluation.

Compatibility with other medicines

Formal systemic drug interaction studies have not been conducted due to the low systemic bioavailability of podofilox under recommended usage conditions. However, concurrent application of other topical medications, caustic agents, or skin irritants on the same anatomical area is strictly contraindicated. Combining podofilox with other podophyllin-containing products increases the risk of local tissue toxicity and systemic exposure. Healthcare providers should review all co-administered topical treatments to avoid cumulative cutaneous irritation or unexpected physical drug incompatibilities.

Important precautions

Podofilox solution and gel are intended strictly for external topical use and must never be taken orally or applied near the eyes. If contact with eyes occurs, rinse immediately with large volumes of water and seek medical attention. Caution must be exercised to avoid applying the drug to broken, bleeding, or inflamed skin, as this markedly increases systemic absorption risks. Diagnosis should be confirmed by biopsy if lesions do not respond after 4 treatment cycles or if atypia is suspected. Podofilox is a prescription drug and should only be used by the individual for whom it was prescribed.

Special populations

The safety and efficacy of podofilox during pregnancy have not been established; podofilox should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing mothers should exercise caution, as it is unknown whether topically applied podofilox is excreted in human milk. Pediatric safety and effectiveness in patients under 18 years of age have not been demonstrated in clinical trials. Geriatric patients exhibit similar safety profiles, though dosing considerations remain governed by lesion area and total daily application limits.

Storage and expiration

Podofilox formulations should be stored at controlled room temperature between 68°F and 77°F (20°C to 25°C), with brief excursions permitted between 59°F and 86°F (15°C to 30°C). Keep the container tightly closed, upright, and away from direct heat, open flames, and moisture. Store out of reach of children and pets. Do not use the formulation beyond the printed expiration date located on the bottle, tube, or outer packaging. Expired or unused medication should be disposed of in accordance with local environmental regulations.

Common questions

How many treatment cycles of podofilox can be performed?

Podofilox therapy is typically administered in up to 4 consecutive 7-day cycles (3 days of application followed by 4 days without treatment). If visible lesions persist after 4 full cycles, therapy should be discontinued and the patient should consult their prescribing physician for alternative clinical options.

What should I do if podofilox accidentally gets on surrounding healthy skin?

If podofilox contacts healthy, non-lesional skin, wipe it off immediately with a clean tissue and wash the area thoroughly with mild soap and warm water. Excess application to normal skin can cause significant local irritation, burning, and tissue breakdown.

Can podofilox be used for internal lesions such as intravaginal or urethral warts?

No. Podofilox is strictly limited to external cutaneous application. It is not approved or safe for internal use, including inside the vagina, cervical canal, urethra, or rectum, due to risks of severe mucosal erosion and enhanced systemic absorption.

What happens if a scheduled application dose is missed?

If a dose is missed during a 3-day treatment window, apply it as soon as remembered unless it is almost time for the next scheduled application. Do not double the dose or apply extra quantity to compensate for a missed application.

In accordance with FDA requirements.

This material is educational. Only a licensed prescriber can determine whether a medication is appropriate for you.

Additional information
Dosage

20% 10 ml

Package

1 flacons

,

3 flacons

,

5 flacons

Ενεργός Ουσία